Moderna Inc (NASDAQ: MRNA)’s CEO said last week that it will not seek emergency use authorization for its coronavirus vaccine candidate mRNA-1273 before the Nov. 3 U.S. presidential election.Trial Enrollment Hits 94% Of Target: Moderna’s vaccine candidate is in a large-scale Phase 3 trial dubbed COVE with a target enrollment of 30,000 participants.About 28,043, or 93.5%, of the targeted participants have been enrolled into the study, Moderna said in a late Friday tweet.Of those people, 19,369 have been administered a second dose.> As of Friday, October 2, 2020, 28,043 participants have been enrolled in the Phase 3 COVE study …read more
Source:: Yahoo Finance
